We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

83 hedge funds and large institutions have $226M invested in Theravance Biopharma in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 29 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 29

8% less funds holding

Funds holding: 90 → 83 (-7)

24% less capital invested

Capital invested by funds: $297M → $226M (-$71M)

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

100% less call options, than puts

Call options by funds: $4K | Put options by funds: $989K

Holders
83
Holders Change
-7
Holders Change %
-7.78%
% of All Funds
2.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
7
Increased
28
Reduced
29
Closed
13
Calls
$4K
Puts
$989K
Net Calls
-$985K
Net Calls Change
-$801K

Top Buyers

1
WIM
Woodford Investment Management
United Kingdom
+$4.59M
2
RSCM
Rock Springs Capital Management
Maryland
+$1.62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.27M
4
Millennium Management
Millennium Management
New York
+$992K
5
PI
Putnam Investments
Massachusetts
+$951K

Top Sellers

1
AC
Armistice Capital
New York
-$12.7M
2
Capital World Investors
Capital World Investors
California
-$4.84M
3
BB
BB Biotech
Switzerland
-$4.68M
4
EAM
Eagle Asset Management
Florida
-$3.63M
5
Renaissance Technologies
Renaissance Technologies
New York
-$3.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$70.6M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$18.3M +$764K +59,985 +4%
BFA
3
BlackRock Fund Advisors
California
$17.6M -$1.38M -108,249 -6%
First Manhattan
4
First Manhattan
New York
$12.8M -$157K -12,294 -1%
O
5
OppenheimerFunds
New York
$12M -$70.5K -5,540 -0.5%
Norges Bank
6
Norges Bank
Norway
$8.68M -$2.68M -210,661 -21%
State Street
7
State Street
Massachusetts
$8.61M -$1.02M -80,414 -9%
BIT
8
BlackRock Institutional Trust
California
$7.21M -$872K -68,448 -9%
RSCM
9
Rock Springs Capital Management
Maryland
$6.62M +$1.62M +127,500 +27%
FAM
10
Foundation Asset Management
New York
$6.42M – – –
CC
11
Clearline Capital
New York
$5.68M +$367K +28,812 +6%
RA
12
Royce & Associates
New York
$5.65M +$344K +27,000 +6%
CPM
13
Chesapeake Partners Management
Maryland
$4.71M +$409K +32,100 +8%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$4.51M -$514K -40,369 -9%
WIM
15
Woodford Investment Management
United Kingdom
$3.96M +$4.59M +360,685 New
Northern Trust
16
Northern Trust
Illinois
$2.88M -$50.4K -3,956 -1%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.86M +$92K +7,228 +4%
RP
18
Reinhart Partners
Wisconsin
$1.8M -$24.7K -1,940 -1%
State of New Jersey Common Pension Fund D
19
State of New Jersey Common Pension Fund D
New Jersey
$1.76M +$446K +35,000 +28%
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$1.54M +$197K +15,490 +12%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.41M -$9.36K -735 -0.6%
Millennium Management
22
Millennium Management
New York
$1.35M +$992K +77,906 +172%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$1.34M +$1.27M +100,049 +447%
Bank of America
24
Bank of America
North Carolina
$1.33M +$433K +33,971 +39%
CS
25
Credit Suisse
Switzerland
$1.12M -$365K -28,649 -22%
1
2 3 4

TBPH Hedge Fund Activity: Q3 2015 in Review

83 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2015, worth a combined $226M — down 24% from $297M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of TBPH and 7 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 28 added.

The largest buyer was Woodford Investment Management, opening a new position worth an estimated $4.59M. The largest seller was Armistice Capital, exiting entirely with an estimated $12.7M sold.

  • 83 institutional investors held Theravance Biopharma (TBPH) as of Q3 2015, down from 90 in Q2 2015.
  • Funds reported $226M of Theravance Biopharma stock for Q3 2015, down 24% quarter-over-quarter.
  • 7 funds opened new Theravance Biopharma positions in Q3 2015 and 13 closed out, a net change of -6 holders.
  • The largest Theravance Biopharma buyer in Q3 2015 was Woodford Investment Management, an estimated $4.59M added.
  • The largest Theravance Biopharma seller in Q3 2015 was Armistice Capital, an estimated $12.7M sold.

Based on aggregated 13F filings for Q3 2015.